{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T07:44:28Z","timestamp":1788335068943,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Lysosomal Disease Network","award":["5U54NS065768-05"],"award-info":[{"award-number":["5U54NS065768-05"]}]},{"name":"Lysosomal Disease Network","award":["N004689101"],"award-info":[{"award-number":["N004689101"]}]}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.ymgme.2017.05.006","type":"journal-article","created":{"date-parts":[[2017,5,18]],"date-time":"2017-05-18T16:37:26Z","timestamp":1495125446000},"page":"76-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["High dose IVIG successfully reduces high rhGAA IgG antibody titers in a CRIM-negative infantile Pompe disease patient"],"prefix":"10.1016","volume":"122","author":[{"given":"Mugdha","family":"Rairikar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoheb B.","family":"Kazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crista","family":"Walters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya S.","family":"Kishnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2017.05.006_bb0005","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fnagi.2014.00177","article-title":"Pompe disease: from pathophysiology to therapy and back again","volume":"6","author":"Lim","year":"2014","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ymgme.2017.05.006_bb0010","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2017.05.006_bb0015","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1542\/peds.112.2.332","article-title":"The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature","volume":"112","author":"van den Hout","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2017.05.006_bb0020","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jpeds.2010.11.053","article-title":"Later-onset Pompe disease: early detection and early treatment initiation enabled by newborn screening","volume":"158","author":"Chien","year":"2011","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2017.05.006_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajmg.c.31324","article-title":"The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management","volume":"160C","author":"Kishnani","year":"2012","journal-title":"Am. J. Med. Genet. C: Semin. Med. Genet."},{"key":"10.1016\/j.ymgme.2017.05.006_bb0030","doi-asserted-by":"crossref","DOI":"10.1097\/GIM.0b013e3181a87867","article-title":"Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker","volume":"11","author":"Young","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2017.05.006_bb0035","doi-asserted-by":"crossref","first-page":"e67052","DOI":"10.1371\/journal.pone.0067052","article-title":"Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile Pompe disease: a step towards improving the efficacy of ERT","volume":"8","author":"Banugaria","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2017.05.006_bb0040","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10545-015-9898-5","article-title":"Response of 33 UK patients with infantile-onset Pompe disease to enzyme replacement therapy","volume":"39","author":"Broomfield","year":"2016","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2017.05.006_bb0045","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2017.05.006_bb0050","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10545-014-9707-6","article-title":"Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease","volume":"38","author":"van Gelder","year":"2015","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2017.05.006_bb0055","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2017.05.006_bb0060","series-title":"Lumizyme R [Package Insert]","year":"2016"},{"key":"10.1016\/j.ymgme.2017.05.006_bb0065","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jpeds.2013.03.002","article-title":"B-cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease","volume":"163","author":"Elder","year":"2013","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2017.05.006_bb0070","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1750-1172-8-90","article-title":"Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy","volume":"8","author":"Prater","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2017.05.006_bb0075","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1586\/eci.12.40","article-title":"Immune modulation in Pompe disease treated with enzyme replacement therapy","volume":"8","author":"Banugaria","year":"2012","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"10.1016\/j.ymgme.2017.05.006_bb0080","doi-asserted-by":"crossref","first-page":"e86821","DOI":"10.1172\/jci.insight.86821","article-title":"Durable and sustained immune tolerance to ERT in Pompe disease with entrenched immune responses","volume":"1","author":"Kazi","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymgme.2017.05.006_bb0085","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ajmg.c.31319","article-title":"Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10years of clinical laboratory testing experience","volume":"160C","author":"Bali","year":"2012","journal-title":"Am. J. Med. Genet. C: Semin. Med. Genet."},{"key":"10.1016\/j.ymgme.2017.05.006_bb0090","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1086\/339691","article-title":"Homozygosity for multiple contiguous single-nucleotide polymorphisms as an indicator of large heterozygous deletions: identification of a novel heterozygous 8-kb intragenic deletion (IVS7\u201319 to IVS15\u201317) in a patient with glycogen storage disease type II","volume":"70","author":"Huie","year":"2002","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2017.05.006_bb0095","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1056\/NEJMc0806809","article-title":"Elimination of antibodies to recombinant enzyme in Pompe's disease","volume":"360","author":"Mendelsohn","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2017.05.006_bb0100","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2017.05.006_bb0105","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ymgme.2011.08.003","article-title":"Atypical immunologic response in a patient with CRIM-negative Pompe disease","volume":"104","author":"Abbott","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2017.05.006_bb0110","first-page":"1","article-title":"Clinical use and therapeutic potential of IVIG\/SCIG, plasma-derived IgA or IgM, and other alternative immunoglobulin preparations","author":"Sp\u00e4th","year":"2016","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"10.1016\/j.ymgme.2017.05.006_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2016.09.023","article-title":"Update on the use of immunoglobulin in human disease: a review of evidence","author":"Perez","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ymgme.2017.05.006_bb0120","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","article-title":"Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin","volume":"345","author":"Kazatchkine","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2017.05.006_bb0125","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature10134","article-title":"Intravenous gammaglobulin suppresses inflammation through a novel TH2 pathway","volume":"475","author":"Anthony","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ymgme.2017.05.006_bb0130","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nri3401","article-title":"Intravenous immunoglobulin therapy: how does IgG modulate the immune system?","volume":"13","author":"Schwab","year":"2013","journal-title":"Nat. Rev. Immunol."},{"issue":"19","key":"10.1016\/j.ymgme.2017.05.006_bb0140","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1212\/WNL.0b013e3182553c11","article-title":"Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy","volume":"78","author":"Ebbink","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2017.05.006_bb0145","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ajmg.c.31323","article-title":"Cognitive and adaptive functioning of children with infantile Pompe disease treated with enzyme replacement therapy: long-term follow-up","volume":"160C","author":"Spiridigliozzi","year":"2012","journal-title":"Am. J. Med. Genet. C Semin. Med. Genet."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719217301634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719217301634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T18:23:34Z","timestamp":1535826214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719217301634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":28,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S1096719217301634"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2017.05.006","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High dose IVIG successfully reduces high rhGAA IgG antibody titers in a CRIM-negative infantile Pompe disease patient","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2017.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}